• 10 maja, 2021
imsc-krakow

Ocena nowatorskiej technologii wielu analitów

Ocena nowatorskiej technologii wielu analitów opartej na cząsteczkach do wykrywania przeciwciał przeciw fibrylarynie

Systemic sclerosis (SSc) is a heterogeneous autoimmune illness related to a number of anti-nuclear antibodies (ANA), together with these within the classification standards (anti-centromere, anti-topoisomerase I (Scl-70), anti-RNA Pol III). Nonetheless, the presence of much less frequent antibodies comparable to anti-fibrillarin (U3-RNP) that generate a clumpy nucleolar sample by HEp-2 oblique immunofluorescence assay (IFA, ICAP AC-9) are thought of illness particular and are with medical subsets of SSc, due to this fact enjoying a job in analysis and prognosis. A particular and delicate anti-fibrillarin assay can be an vital addition to serological analysis and analysis of SSc. The objective of this examine was to judge a brand new particle-based multi-analyte expertise (PMAT) for the measurement of anti-fibrillarin antibodies.

A complete of 149 affected person samples have been collected together with 47 samples from France (Lyon and Paris, n = 32) and Italy (Careggi Hospital, Florence, n = 15) chosen primarily based on AC-9 HEp-2 IFA staining (> 1:640, clumpy nucleolar sample) and 102 non-SSc controls (inflammatory bowel illness (IBD) n = 20, Sjögren’s syndrome (SjS) n = 20, infectious illness (ID) n = 7, systemic lupus erythematosus (SLE) n = 17, rheumatoid arthritis (RA) n = 17, and wholesome people (HI) n = 21). All samples have been examined on the anti-fibrillarin PMAT assay (analysis use solely, Inova Diagnostics, USA). Moreover, the 47 anti-fibrillarin optimistic samples have been additionally examined on PMAT assays for detecting different autoantibodies in ANA-associated rheumatic illnesses (AARD). Anti-fibrillarin antibody knowledge carried out by fluorescence enzyme immunoassay (FEIA, Thermo Fisher, Germany) was obtainable for 34 samples. The anti-fibrillarin PMAT assay was optimistic in 31/32 (96.9%, France) and 12/15 (80.0%, Italy) of samples preselected primarily based on the AC-9 IIF sample (distinction p = 0.09).

Collectively, the PMAT assay confirmed 91.5% (95% confidence interval (CI): 80.1-96.6%) sensitivity with 100.0% (95% CI: 96.4-100.0%) specificity in non-SSc controls. Robust settlement was discovered between PMAT and FEIA with 100.0% optimistic qualitative settlement (34/34) and quantitative settlement (Spearman’s rho = 0.89, 95% CI: 0.77.9-0.95%, p < 0.0001). Though most anti-fibrillarin optimistic samples have been mono-specific (69.8%), some expressed extra antibodies (particularly Scl-70, centromere, dsDNA, Ro52, Ro60, SS-B, Ribo-P, DFS70, and EJ).

In conclusion, this primary examine on anti-fibrillarin antibodies measured utilizing a novel PMAT assay exhibits promising outcomes the place the brand new PMAT assay had excessive degree of settlement to FEIA for the detection of anti-fibrillarin antibodies. The provision of novel AFA assays comparable to PMAT would possibly facilitate the medical deployment, extra research, standardization efforts, and doubtlessly consideration of AFA for subsequent generations of the classification standards.

imsc-krakow
imsc-krakow

Mouse Monoclonal anti-human Tetranectin (CLEC-3B)

hAP-0639 100ug
EUR 250

Sheep Polyclonal anti-Human Tetranectin (CLEC-3B)

hAP-5777 50ug
EUR 400

OKRC00302-96W - CLEC-2 ELISA Kit (Human)

OKRC00302-96W 96Wells
EUR 525

Human CLEC-2 / CLEC1B Protein, His Tag (MALS verified)

CL2-H5247 100ug
EUR 2749.9
Description: Human CLEC-2, His Tag (CL2-H5247) is expressed from human 293 cells (HEK293). It contains AA Ser 55 - Pro 229 (Accession # Q9P126-1).

Human C-type lectin-like receptor 1(CLEC-1) ELISA Kit

YLA4238HU-48T 48T Ask for price

Human C-type lectin-like receptor 1(CLEC-1) ELISA Kit

YLA4238HU-96T 96T Ask for price

Human CLEC-2 / CLEC1B Protein, Fc Tag (MALS & SPR verified)

CL2-H5254 100ug
EUR 2493.1
Description: Human CLEC-2, Fc Tag (CL2-H5254) is expressed from human 293 cells (HEK293). It contains AA Ser 55 - Pro 229 (Accession # Q9P126-1).

Human C-type lectin-like receptor 2(CLEC-2) Elisa Kit

YLA4051HU-48T 48T Ask for price

Human C-type lectin-like receptor 2(CLEC-2) Elisa Kit

YLA4051HU-96T 96T Ask for price

Recombinant Caenorhabditis Elegans clec-159 Protein (aa 1-207)

VAng-Ly3238-1mgEcoli 1 mg (E. coli)
EUR 4216.8
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 159 (clec-159), recombination protein.

Recombinant Caenorhabditis Elegans clec-159 Protein (aa 1-207)

VAng-Ly3238-500gEcoli 500 µg (E. coli)
EUR 3013.2
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 159 (clec-159), recombination protein.

Recombinant Caenorhabditis Elegans clec-159 Protein (aa 1-207)

VAng-Ly3238-50gEcoli 50 µg (E. coli)
EUR 2056.8
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 159 (clec-159), recombination protein.

Recombinant Caenorhabditis Elegans clec-161 Protein (aa 21-862)

VAng-Ly3239-inquire inquire Ask for price
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 161 (clec-161), partial, recombination protein.

Recombinant Caenorhabditis Elegans clec-162 Protein (aa 18-313)

VAng-Ly3240-1mgEcoli 1 mg (E. coli)
EUR 4893.6
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 162 (clec-162), recombination protein.

Recombinant Caenorhabditis Elegans clec-162 Protein (aa 18-313)

VAng-Ly3240-500gEcoli 500 µg (E. coli)
EUR 3474
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 162 (clec-162), recombination protein.

Recombinant Caenorhabditis Elegans clec-162 Protein (aa 18-313)

VAng-Ly3240-50gEcoli 50 µg (E. coli)
EUR 2370
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 162 (clec-162), recombination protein.

Recombinant Caenorhabditis Elegans clec-91 Protein (aa 22-225)

VAng-Ly3241-1mgEcoli 1 mg (E. coli)
EUR 4200
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 91 (clec-91), recombination protein.

Recombinant Caenorhabditis Elegans clec-91 Protein (aa 22-225)

VAng-Ly3241-500gEcoli 500 µg (E. coli)
EUR 2997.6
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 91 (clec-91), recombination protein.

Recombinant Caenorhabditis Elegans clec-91 Protein (aa 22-225)

VAng-Ly3241-50gEcoli 50 µg (E. coli)
EUR 2040
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 91 (clec-91), recombination protein.

Mouse Monoclonal anti-human CLEC5A (MDL-1)

hAP-1206 50ug
EUR 400

Sheep Polyclonal anti-Human CLEC5A (MDL-1)

hAP-5783 50ug
EUR 400

Mouse Monoclonal anti-human CLEC9a (DNGR-1)

hAP-0621 100ug
EUR 250

Sheep Polyclonal anti-Human Clec9a (DNGR-1)

hAP-5967 50ug
EUR 400

Mouse Monoclonal anti-human CLEC7A (Dectin-1)

hAP-1209 50ug
EUR 400

Sheep Polyclonal anti-Human CLEC7A (Dectin-1)

hAP-5786 50ug
EUR 400

Anti-Human CLEC9a Antibody

101-M232 100 µg
EUR 399
Description: CLEC9A, a group V C-type lectin-like receptor, is located in the “Dectin-1 cluster” of related receptors, which are encoded within the natural killer (NK)-gene complex. Expression of human CLEC9A is highly restricted in peripheral blood, being detected only on BDCA3+ dendritic cells and on a small subset of CD14+CD16- monocytes. CLEC9A is expressed at the cell surface as a glycosylated dimer and can mediate endocytosis, but not phagocytosis. CLEC9A possesses a cytoplasmic immunoreceptor tyrosine-based activation-like motif that can recruit Syk kinase, and it was shown, using receptor chimeras, that this receptor can induce proinflammatory cytokine production.

PE anti-human CD301 (CLEC10A)

E16FHP301-025 25 tests
EUR 541.67
Description: Available in various conjugation types.

PE anti-human CD301 (CLEC10A)

E16FHP301-100 100 tests
EUR 1278.33
Description: Available in various conjugation types.

APC anti-human CD301 (CLEC10A)

E16FHA301-025 25 tests
EUR 563.33
Description: Available in various conjugation types.

APC anti-human CD301 (CLEC10A)

E16FHA301-100 100 tests
EUR 1343.33
Description: Available in various conjugation types.

Purified anti-human CD301 (CLEC10A)

E16FHU301-025U 25 μg
EUR 325
Description: Available in various conjugation types.

Purified anti-human CD301 (CLEC10A)

E16FHU301-100U 100 μg
EUR 758.33
Description: Available in various conjugation types.

Lenti ORF particles, Clec4a (GFP-tagged ORF) - Rat C-type (calcium dependent, carbohydrate recognition domain) lectin, superfamily member 6 (Clec

RR205033L4V 200 µl Ask for price

Sheep Polyclonal anti-Human CLEC4D (CLECSF8)

hAP-5780 50ug
EUR 400

Mouse Monoclonal anti-human CLEC14A

hAP-1213 50ug
EUR 400

Sheep Polyclonal anti-Human CLEC14A

hAP-5793 50ug
EUR 400

Human CLEC12A / MICL / CLL-1 Protein, His Tag

CLA-H5245 50ug
EUR 3092.3
Description: Human CLEC12A, His Tag (CLA-H5245) is expressed from human 293 cells (HEK293). It contains AA His 65 - Ala 265 (Accession # Q5QGZ9-2).

Human CLEC4E Antibody

32522-05111 150 ug
EUR 215

Human CLEC2B Antibody

33430-05111 150 ug
EUR 215

Rat Monoclonal anti-mouse CLEC9a (DNGR-1)

mAP-0399 50ug
EUR 400

Mouse Monoclonal anti-human SCGF (CLEC11A)

hAP-0533 100ug
EUR 250

Mouse Monoclonal anti-human CLEC12A (MICL)

hAP-1211 50ug
EUR 400

Sheep Polyclonal anti-Human SCGF (CLEC10A)

hAP-5788 50ug
EUR 400

Sheep Polyclonal anti-Human CLEC12A (MICL)

hAP-5789 50ug
EUR 400

Mouse Monoclonal anti-human CLEC10A (CD301)

hAP-1210 50ug
EUR 400

Mouse Monoclonal anti-human CLEC13A (CD302)

hAP-1212 50ug
EUR 400

Mouse Monoclonal anti-human CLEC15A (KLRG1)

hAP-1214 50ug
EUR 400

Sheep Polyclonal anti-Human CLEC10A (CD301)

hAP-5787 50ug
EUR 400

Sheep Polyclonal anti-Human CLEC13A (CD302)

hAP-5790 50ug
EUR 400

Mouse Monoclonal anti-human CLEC4D (CLESF8)

hAP-1203 50ug
EUR 400

Sheep Polyclonal anti-mouse CLEC9a (DNGR-1)

mAP-5098 50ug
EUR 400

CLEC10A sgRNA CRISPR Lentivector (Human) (Target 1)

K0463402 1.0 ug DNA
EUR 184.8

CLEC11A sgRNA CRISPR Lentivector (Human) (Target 1)

K0463502 1.0 ug DNA
EUR 184.8

CLEC12A sgRNA CRISPR Lentivector (Human) (Target 1)

K0463602 1.0 ug DNA
EUR 184.8

CLEC12B sgRNA CRISPR Lentivector (Human) (Target 1)

K0463702 1.0 ug DNA
EUR 184.8

CLEC14A sgRNA CRISPR Lentivector (Human) (Target 1)

K0463802 1.0 ug DNA
EUR 184.8

CLEC16A sgRNA CRISPR Lentivector (Human) (Target 1)

K0463902 1.0 ug DNA
EUR 184.8

CLEC17A sgRNA CRISPR Lentivector (Human) (Target 1)

K0464002 1.0 ug DNA
EUR 184.8

CLEC18A sgRNA CRISPR Lentivector (Human) (Target 1)

K0464102 1.0 ug DNA
EUR 184.8

CLEC18B sgRNA CRISPR Lentivector (Human) (Target 1)

K0464202 1.0 ug DNA
EUR 184.8

CLEC18C sgRNA CRISPR Lentivector (Human) (Target 1)

K0464302 1.0 ug DNA
EUR 184.8

Recombinant Human Dectin-1/CLEC7A Protein

PKSH031752-100ug 100ug
EUR 940
Description: Human

Human CLEC4A Antibody Pair Set

ABPR-ZB029 5 plates, 15 plates Ask for price
Description: Quantitative determination of Human CLEC4A

Human CLEC4D Antibody Pair Set

ABPR-ZB201 5 plates, 15 plates Ask for price
Description: Quantitative determination of Human CLEC4D

Nori® Human Dectin-1/CLEC7A ELISA Kit

GR111344 96-well
EUR 461

Recombinant Human CLEC7A/Dectin-1/CD369 Protein

RP01523 20μg
EUR 162.5

Sheep Polyclonal anti-Human CLEC13E (Mrc-2)

hAP-5792 50ug
EUR 400

Mouse Monoclonal anti-human DCIR (CLEC4A)

hAP-0237 100ug
EUR 250

Sheep Polyclonal anti-Human DCIR (CLEC4A)

hAP-5778 50ug
EUR 400

Recombinant Human CLEC12A/CLL-1/DCAL2 Protein (His Tag)

PKSH030977-100ug 100ug
EUR 1268
Description: Human

Recombinant Human CLEC12A/CLL-1/DCAL2 Protein (His Tag)

PKSH030977-1mg 1mg
EUR 7480
Description: Human

anti- CLEC11A antibody

FNab01746 100µg
EUR 606.3
Description: Antibody raised against CLEC11A

anti- CLEC12B antibody

FNab01747 100µg
EUR 658.5
Description: Antibody raised against CLEC12B

anti- CLEC14A antibody

FNab01748 100µg
EUR 658.5
Description: Antibody raised against CLEC14A

anti- CLEC18A antibody

FNab01749 100µg
EUR 658.5
Description: Antibody raised against CLEC18A

Mouse Monoclonal anti-human CLEC5B (CD161)

hAP-1207 50ug
EUR 400

Sheep Polyclonal anti-Human NKp80 (CLEC5C)

hAP-5784 50ug
EUR 400

Human CLEC12A / MICL / CLL-1 Protein, Fc Tag (MALS verified)

CLA-H5266 50ug
EUR 3242.1
Description: Human CLEC12A, Fc Tag (CLA-H5266) is expressed from human 293 cells (HEK293). It contains AA His 65 - Ala 265 (Accession # Q5QGZ9-2).

Mouse Monoclonal anti-Human CD371 (CLEC12A) Antibody

xAP-0253 100ug
EUR 280

Mouse Monoclonal anti-human CLEC4H1 (ASGR1)

hAP-1205 50ug
EUR 400

Mouse Monoclonal anti-human CLEC4G (LSECtin)

hAP-1204 50ug
EUR 400

Sheep Polyclonal anti-Human CLEC4G (LSECtin)

hAP-5781 50ug
EUR 400

FITC-Labeled Human CLEC12A / MICL / CLL-1 Protein, His Tag

CLA-HF247 25ug
EUR 2471.7
Description: FITC-Labeled Human CLEC12A, His Tag (CLA-HF247) is expressed from human 293 cells (HEK293). It contains AA His 65 - Ala 265 (Accession # Q5QGZ9-2). It is the FITC labeled form of Human CLEC12A, His Tag (CLA-H5245).

CLECL1 (untagged)-Human C-type lectin-like 1 (CLECL1)

SC306703 10 µg Ask for price

CLEC1A sgRNA CRISPR Lentivector (Human) (Target 1)

K0461402 1.0 ug DNA
EUR 184.8

CLEC1B sgRNA CRISPR Lentivector (Human) (Target 1)

K0461502 1.0 ug DNA
EUR 184.8

CLEC2A sgRNA CRISPR Lentivector (Human) (Target 1)

K0461602 1.0 ug DNA
EUR 184.8

CLEC2B sgRNA CRISPR Lentivector (Human) (Target 1)

K0461702 1.0 ug DNA
EUR 184.8

CLEC2D sgRNA CRISPR Lentivector (Human) (Target 1)

K0461802 1.0 ug DNA
EUR 184.8

CLEC2L sgRNA CRISPR Lentivector (Human) (Target 1)

K0461902 1.0 ug DNA
EUR 184.8

Porównywalne endemiczne przeciwciała specyficzne dla nukleoproteiny koronawirusa u pacjentów z łagodnym i ciężkim Covid-19

The severity of illness of Covid-19 is very variable, starting from asymptomatic to essential respiratory illness and demise. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) might hypothetically contribute to this variability. We herein studied if eCoV Nucleoprotein (N)-specific antibodies within the sera of sufferers with delicate or extreme Covid-19 are related to Covid-19 severity.

There have been comparable ranges of eCoV N-specific antibodies early and throughout the first month of an infection in Covid-19 sufferers with delicate and extreme signs, and wholesome SARS-COV-2-negative topics. These outcomes warrant additional research to analyze the potential position of eCoV-specific antibodies in immunity to SARS-CoV-2 an infection. This text is protected by copyright. All rights reserved.

TOP-Plus to wszechstronna platforma biosensoryczna do monitorowania trwałości przeciwciał SARS-CoV-2 

Background: Low preliminary SARS-CoV-2 antibody titers dropping to undetectable ranges inside months after an infection have raised considerations over long run immunity. Each the antibody ranges and avidity of the antibody-antigen interplay ought to be examined to perceive the standard of the antibody response.

Strategies: A testing-on-a-probe “plus” panel (TOP-Plus) was developed, which included a newly developed avidity assay constructed into the beforehand described SARS-CoV-2 TOP assays that measured complete antibody (TAb), surrogate neutralizing antibody (SNAb), IgM and IgG on a flexible biosensor platform. TAb and SNAb ranges have been in contrast with avidity in beforehand contaminated people at 1.three and 6.2 months post-infection in paired samples from 80 COVID-19 sufferers. Sera from SARS-CoV-2 vaccinated people have been additionally evaluated for antibody avidity.

Outcomes: The newly designed avidity assay on this TOP panel correlated nicely with a reference Bio-Layer Interferometry avidity assay (r=0.88). The imprecision of the TOP avidity assay was lower than 10%. Though TAb and neutralization exercise (by SNAb) decreased between 1.three and 6.2 months post-infection, the antibody avidity elevated considerably (P < 0.0001). Antibody avidity in 10 SARS-CoV-2 vaccinated people (median 28 days post-vaccination) was corresponding to the measured antibody avidity in contaminated people (median 26 days post-infection).

Conclusion: This extremely exact and versatile TOP-Plus panel with the power to measure SARS-CoV-2 TAb, SNAb, IgG and IgM antibody ranges and avidity of particular person sera on one sensor can change into a helpful asset in monitoring not solely SARS-CoV-2-infected sufferers, but in addition the standing of people’ COVID-19 vaccination response.

Brak dowodów na zakażenie makrofagami pochodzącymi z ludzkich monocytów i nasilenie zakażenia SARS-CoV-2 za pośrednictwem przeciwciał

Vaccines are important to manage the unfold of extreme acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and to guard the susceptible inhabitants. Nonetheless, one security concern of vaccination is the doable growth of antibody-dependent enhancement (ADE) of SARS-CoV-2 an infection. The potential an infection of Fc receptor bearing cells comparable to macrophages, would assist continued virus replication and inflammatory responses, and thereby doubtlessly worsen the medical final result of COVID-19.

Right here we show that SARS-CoV-2 and SARS-CoV neither infect human monocyte-derived macrophages (hMDM) nor induce inflammatory cytokines in these cells, in sharp distinction to Center East respiratory syndrome (MERS) coronavirus and the frequent chilly human coronavirus 229E. Moreover, serum from convalescent COVID-19 sufferers neither induced enhancement of SARS-CoV-2 an infection nor innate immune response in hMDM. Though, hMDM expressed angiotensin-converting enzyme 2, no or very low ranges of transmembrane protease serine 2 have been discovered. These outcomes assist the view that ADE is probably not concerned within the immunopathological processes related to COVID-19, nonetheless, extra research are essential to know the potential contribution of antibodies-virus complexes with different cells expressing FcR receptors.

Dodaj komentarz

Twój adres e-mail nie zostanie opublikowany. Wymagane pola są oznaczone *